Eva Gabaldon posted this:
Licensing Manager at Spanish National Research Council
Maria João Cardoso posted this:
Science and Technology Manager at UATEC - Unidade de Transferência de Tecnologia
Universidad de Alcalá-OTRI posted this:Derivatives of Indolin-2-one and its therapeutic use in inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer diseases.The research group of “Neuroendocrinology of the cannabinoid / vanilloid system” of the University of Alcalá, in collaboration with researchers from the Institute of Medical Chemistry of CSIC, have developed a series of compounds derived from indolin-2-one, emphasizing the pharmaceutical compositions containing in the compounds and their use for the treatment of diseases mediated by AMPK (AMP-activated kinase), particularly inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer. The group is looking for companies in the pharmaceutical and health sector with the objective of reaching technical cooperation agreements, commercial agreements with technical assistance or patent licensing.
Mª Eugenia Garcés Castellote posted this:
Commercialization Specialist at Universidad de Alcalá-OTRI
Universidad de Alcalá-OTRI posted this:Carbosilane dendrons functionalized with fatty acids: Formation of micelles and uses in biomedicine as antiviral, antibacterial, antiprionic, antimicrobial and drug transporters.The research group of the University of Alcalá in «Dendrimers for biomedical applications» presents the following invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives of these. Its main field of application is in biomedicine, as non-viral transport agents, as drug transporters, to elaborate a drug, as antimicrobial, antiviral or antipyretic agents. In the environmental sector we also find its application as biocides for water treatment. The group seeks to reach license agreements, collaboration or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers and their use as antiviralsThe research group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents these highly branched macromolecules synthesized from a polyfunctional nucleus, of carbosilane structure and functionalized in its periphery with anionic groups that give the macromolecule a negative net charge. In addition, the invention relates to the use of the dendrimers as an antimicrobial and the process for obtaining them. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies in the biotechnology, pharmaceutical and biomedicine sectors in general.
Merck KGaA posted this:Technology for Lysophosphatidic Acid (LPA) Receptor antagonistsMerck has developed and patented the results of its intense R&D activities for the identification of small organic molecules as antagonists to certain LPA receptors (LPAR1, -R2, -R3). Herein described are LPA-R2 receptor selective inhibitors. Based upon a rational screening cascade established, compounds have been identified and characterized with regard to their specific in vitro and cellular activities. The package includes access to the IP, experimental results, and materials. Merck offers the unique chance to acquire this promising program.
Merck KGaA posted this:Technology for Serum and Glucocorticoid regulated kinase (SGK) inhibitorsMerck KGaA, Darmstadt, Germany, has developed and patented the results of its intense R&D activities for the identification of small organic molecules as SGK1 inhibitors. Based upon a rational screening cascade established, compounds have been identified and characterized with regard to their specific in vitro, cellular and in vivo activities. The package includes access to the IP, experimental results, and materials. Merck KGaA, Darmstadt, Germany, offers the unique chance to acquire this promising program.
Cracow University of Technology posted this:The new lupeol derivative and the method of obtaining.This invention relates to a biologically active compound, the derivative of natural triterpene lupeol. This derivative is active for human skin cells, improving their proliferation process. In addition, the substance has the ability to neutralize free radicals. The described derivative can be used as an active ingredient in pharmaceutical and cosmetic preparations dedicated for damaged or burned skin, as well as in anti-aging cosmetics.
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers with polyphenolic groups. Uses as antioxidants and anticancer.The "Dendrimer for biomedical applications Research Group" at Alcalá University presents dendritic macromolecules with skeleton of carbosilane nature that contain in their structure polyphenolic groups (GPF). These compounds are powerful antioxidants and free radical scavengers, as well as anticancer agents, with application in sectors such as food, cosmetics and pharmaceutical industry. The invention provides a process for its procurance and uses.
University of Vigo posted this:Method for the sequential immunochemical evaluation on a same biological sample of NCAM (Neural Cell Adhesion Molecule) protein and its PolySialic Acid (PSA) tail, by western blot coupled to chemiluminiscence detection.The method optimizes the expression assays of PSA-NCAM isoforms in biological samples available in small quantities or restricted (as is the case of human specimens, for example). It improves quantitative and qualitative performance of PSA-NCAM analysis by western blot.
RAMOT at Tel Aviv University Ltd. posted this:A novel behavioral bioassay for preclinical testing and characterization of CNS agentsOur team, including zoologists, statisticians, and computer scientists have developed a new hi-res bioassay for preclinical testing and characterization of CNS agents, extracting key animal-centered parameters of behavior via computerized tracking and measurement of free exploration. The features that distinguish our system and method from other existing systems and methods are: elaborate data preparation for analysis and a methodology that secures replicability of results across laboratories, and exposes active management of kinematic variables. Our measured parameters are carefully designed, animal-centered building blocks of behavior. They are selected on the basis of an in-depth understanding of the mouse’s functional world. These quite unexpected and unusual parameters reflect the animal’s cognitive and emotional state and its information processing capacity; therefore they are most prone to be affected by drugs that act on respective CNS structures that mediate these states. Unlike all other existing systems we expose and quantify the rich and highly organized developmental dynamics of self regulated behavioral growth. The dynamics of this process before and after genetic manipulation and/or pharmacological treatment can now be readily measured by our system, articulating the effects of potential CNS drugs on behavioral growth and decay processes. Project ID : 2-2009-11
RAMOT at Tel Aviv University Ltd. posted this:Oral Mucosa-derived Stem Cells: A Unique Population for the Prevention and Treatment of Ischemic Heart FailureStem cells (SC) are considered crucial building blocks for any regenerative strategy. Adult oral mucosa (OM) is a unique source for generating adult pluripotent stem cell (OPSC) populations. This uniqueness consists in the fact that 95% of the OM whole populations in culture (1st – 8th passages) express markers of embryonic and mesenchymal SC. Thus, in contradistinction to known sources which comprise very low numbers of SC, OPSC generation for clinical use is simple and cost effective and does not require cumbersome cost-consuming purification steps. The general objective is to lay the foundation for the development of a variety of products based on the pluripotency and simple and cost effective generation of billions of OPSC. The major aim of the proposed project is to develop a product for the treatment of ischemic heart failure (IHF). This product which will serve as a proof of concept was selected based on medicals needs, market cap and time to market. The specific aims of the proposal are: 1. To develop a cardiac product aimed at treating ischemic heart failure (IHF). The aim is to test the safety and therapeutic effect of OPSC on experimental IHF in a minipig model. 2. To strengthen the intellectual property by fully characterizing the profile of OPSC. The prevalence of IHF continuously increases (1 million new cases every year in the western world) and currently the market cap is estimated in the range of billions. Project ID : 10-2011-260
RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
UATEC - Unidade de Transferência de Tecnologia posted this:Fluorescent compounds, methods of manufacturing and uses thereofA group of researchers from a Portuguese university developed a family of new fluorophores to be used in biological imaging, either in cells or in entire organisms, in fluorescence microscopy techniques, including live cell imaging. The fluorophores are not toxic to cells and organisms, and light up cells by binding to organelles such as the Golgi apparatus, nucleus, and particularly lipid droplets. Importantly, the fluorophores change color with the polarity of the environment. The university is looking for companies that would be interested in developing this technology further through partnership, or in commercializing the probes through licensing or acquisition of the patent.